Shares in the brain drug developer rose by more than 20% Monday on news of the deal, which will forestall Teva's generic copy of Auvelity from entering the U.S. market until at least 2038.

Shares in biopharmaceutical group Axsome Therapeutics (AXSM) surged 23% today after it said it had settled a legal dispute with peer Teva ...

Non-GAAP net profit was $57.3 million in the fourth quarter, up 70% from the fourth quarter of 2023 and earnings per share ...

With the settlement, Teva will not market the Auvelity generic until September 30, 2038, Axsome said in a Monday press release. Entrance of the generic will be delayed by an additional six months, ...

Truist Securities maintained a positive stance on Axsome Therapeutics (NASDAQ:AXSM), reiterating a Buy rating and a $190.00 ...

Under the agreement, Axsome will grant Teva a license to sell its generic version of Auvelity beginning on or after March 31, 2039, if pediatric exclusivity is granted for Auvelity, or on or after ...

Axsome Therapeutics (AXSM) stock rallied 15% on news the company has settled patent litigation with Teva (TEVA) over a ...

Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...

NEW YORK - Axsome Therapeutics, Inc. (NASDAQ:AXSM), a $5.1 billion market cap biopharmaceutical company with impressive 91% gross profit margins, has reached a settlement agreement with Teva ...

Axsome Therapeutics (AXSM) announced that it has entered into a settlement agreement with Teva Pharmaceuticals (TEVA) resolving all patent ...

Overall, Friday was a good day for southeastern Minnesota girls wrestlers on the opening day of the Section 1&2 tournament.

GLP-1 drugs like Ozempic and Wegovy revolutionized weight loss, but their high cost keeps them out of reach for most ...